Science Innovations: Natural Rainbow Colours Produced  |  Technology Inceptions: Muscope, World’s Smallest Microscope  |  Science Innovations: Ultrasensitive Tactile Sensors for Robots  |  Policy Indications: How Materials Science Helps Contain Contain Covid-19 Spread  |  National Edu News: IIT Hyderabad and PharmCADD signed a pact for the co-development of new drugs   |  Teacher Insights: Be Game  |  Health Monitor: Understanding ‘Haemorrhage'  |  National Edu News: Pallikkutam GlobalConnect#3 on 'Innovative Tools for Effective Teaching'  |  Expert Counsel: The Nine Dash Line  |  National Edu News: Astronomers Find One Group of Appearing and Disappearing Stars  |  Teacher Insights: Bird Book for Children to Love Nature  |  International Edu News: New Model to Fight Social Media Deep Fakes  |  Teacher Insights: Universal Lunch Makes Students Healthier  |  Teacher Insights: Physical Activity Boosts Self Regulation  |  Parent Interventions: Anti-Inflammatory Foods Reduce Blood Fats  |  
January 06, 2021 Wednesday 12:28:02 PM IST

Minister inaugurates CEPI Centralized network lab at DBT-THSTI Faridabad

The Minister for Science & Technology, Health & Family Welfare and Earth Sciences Dr. Harsh Vardhan inaugurated one of the seven labs of the world called as the centralized network lab of Coalition for Epidemic Preparedness Innovations (CEPI) established at Translational Health Science & Technology Institute (THSTI), Faridabad, through virtual platform in New Delhi on 05 January 2020. THSTI is an institute of the Department of Biotechnology (DBT). This is the  only laboratory of such kind in India and is also accredited by National Accreditation Board for Testing and Calibration Laboratories (NABL) (ISO 17025:2017).

The clinical sample testing laboratories selected for this collaborative vaccine network are: Nexelis (Canada) and Public Health England (PHE; UK), VisMederiSrl (Italy), Viroclinics Biosciences BV (The Netherlands), Q2 Solutions (USA), International Centre for Diarrhoeal Disease Research Bangladesh (ICDDR-B, Bangladesh), National Institute for Biological Standards and Control (NIBSC, UK), and Translational Health Sciences and Technological Institute (THSTI, India). CEPI has approved costs of up to the US $16million for this network. All COVID-19 vaccine developers can use this network for free to assess the immunogenicity of their vaccine candidate against a common protocol, using clinical samples from preclinical, Phase I through Phase III trials.


CEPI is an innovative partnership between public, private, philanthropic, and civil organizations, launched at Davos in 2017, to develop vaccines to stop future epidemics. The Department of Biotechnology, Ministry of Science & Technology, Government of India is implementing the Ind-CEPI mission titled ‘India Centric Epidemic Preparedness through Rapid Vaccine Development: Supporting Indian Vaccine Development Aligned with the Global Initiative of the Coalition for Epidemic Preparedness Innovations (CEPI)’. Ind-CEPI Mission aims to strengthen the development of vaccines for the diseases of epidemic potential in India as well as build coordinated preparedness in the Indian public health system and vaccine industry to address existing and emergent infectious threats in India. The major focus at present is to help to evaluate the new Covid-19 vaccines, using standard analysis and same reagents in all labs so that vaccine produced has global acceptance and repeatability of the results, for global use.

The Minister recalled with a great appreciation of how the Indian scientists turned around the country from being an importer to an exporter of world class COVID kits and related products during the last year of difficult times. He reminded that scientists, frontline COVID warriors and general people rose to the occasion and fought the pandemic with focussed attention. He said, “Today, the country is at the forefront of developing vaccines against COVID-19”, and added, “already two of the 30 vaccines have already been cleared by the Drug Controller” for use  and the rest are in advanced stages.


Comments